

Replacement Claims

A11
1. (Amended) A composition comprising a GP88 antisense oligonucleotide wherein said oligonucleotide is capable of hybridizing to at least a portion of the nucleotide sequence from nucleotide 1 to nucleotide 627 or from nucleotide 796 to nucleotide 855 or from nucleotide 1024 to nucleotide 2095 of SEQ ID NO. 16.

A12
15. (Amended) A method of inhibiting the production or biological activity of GP88 comprising the steps of administering ex vivo an effective amount of a GP88 antisense oligonucleotide wherein said oligonucleotide inhibits the production or biological activity of GP88.

A13
24. (Amended) A method for treating diseases associated with alteration of GP88 biological activity comprising the steps of administering an effective amount of a GP88 antisense oligonucleotide wherein said oligonucleotide inhibits the biological activity of GP88.